Department of Surgery, University of California-San Francisco, 513 Parnassus Ave., San Francisco, CA 94143, USA.
Transpl Int. 2012 Dec;25(12):1257-67. doi: 10.1111/j.1432-2277.2012.01565.x. Epub 2012 Sep 21.
This study examined the effect of thymoglobulin induction therapy on leukocyte population dynamics in kidney transplant patients. Patients receiving standard immunosuppression were compared with those who received additional thymoglobulin at the time of kidney transplantation. Thymoglobulin induction led to an immediate and significant decrease of all T cells and NK cells, but not B cells or monocytes. CD8(+) T cells recovered to near pretransplant level by 4 weeks post-transplant. CD4(+) T cells remained at less than 30% of pretransplant level for the entire study period of 78 weeks. Both CD4(+) and CD8(+) T cells showed reduced cytokine production after recovery. Deletion of CD4(+) FOXP3(+) HELIOS(+) regulatory T cells (Tregs) was less profound than that of CD4(+) FOXP3(-) cells, thus the relative percentage of Tregs elevated significantly when compared with pretransplant levels in thymoglobulin-treated patients. In contrast, the percentages of Tregs and their expression of FOXP3 in the standard immunosuppression group decreased steadily and by 12 weeks after transplant the average percentage of Tregs was 56% of the pretransplant level. Thus, thymoglobulin-induced deletion of T cells led to significant and long-lasting alterations of the T-cell compartment characterized by a preservation of Tregs and long-lasting reduction in CD4(+) , and potentially pathogenic, T cells.
本研究探讨了胸腺球蛋白诱导治疗对肾移植患者白细胞群体动力学的影响。接受标准免疫抑制治疗的患者与在肾移植时接受额外胸腺球蛋白治疗的患者进行了比较。胸腺球蛋白诱导导致所有 T 细胞和 NK 细胞立即显著减少,但 B 细胞和单核细胞不受影响。CD8(+)T 细胞在移植后 4 周恢复到接近移植前水平。CD4(+)T 细胞在整个 78 周的研究期间一直低于移植前水平的 30%。CD4(+)和 CD8(+)T 细胞在恢复后细胞因子产生减少。与 CD4(+)FOXP3(-)细胞相比,CD4(+)FOXP3(+)HELIOS(+)调节性 T 细胞(Tregs)的缺失程度较轻,因此与移植前水平相比,胸腺球蛋白治疗患者的 Tregs 相对百分比显著升高。相比之下,标准免疫抑制组 Tregs 的百分比及其 FOXP3 的表达持续下降,移植后 12 周时 Tregs 的平均百分比为移植前水平的 56%。因此,胸腺球蛋白诱导的 T 细胞删除导致 T 细胞群发生显著且持久的改变,其特征是 Tregs 的保留和 CD4(+)、潜在致病性 T 细胞的持续减少。